Welcome to our dedicated page for ChronoScale SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ChronoScale's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ChronoScale's regulatory disclosures and financial reporting.
Ekso Bionics (EKSO) filed its Q3 2025 10‑Q, reporting modest top‑line growth and continued losses amid liquidity pressure. Revenue was $4,227, up slightly from $4,129 a year ago, with gross profit of $2,549 and a net loss of $1,421. Operating loss narrowed to $1,402 from $2,639 as sales and marketing and R&D expenses declined.
Cash was $2,722 as of September 30, 2025. The company retired its $2,000 Banc of California term loan using previously restricted cash and entered a secured promissory note with B. Riley for up to $2,000 at 10% interest plus a $200 exit fee, recorded as a convertible promissory note, net of $1,937. Management disclosed substantial doubt about continuing as a going concern for one year after issuance and estimates cash will fund operations into the first quarter of 2026 while pursuing financings and cost actions.
Year‑to‑date revenue was $9,659 versus $12,835 last year. Deferred revenue totaled $3,331, and the company reported a non‑cancellable backlog of $3,466 expected across 2025–2026. Shares outstanding were 2,623,233 as of October 27, 2025.
Ekso Bionics Holdings, Inc. furnished an update on its financial results for the three and nine months ended September 30, 2025. The company disclosed the results under Item 2.02 and attached a press release as Exhibit 99.1, which is incorporated by reference. The information is being furnished and is not deemed filed under the Exchange Act.
Ekso Bionics Holdings, Inc. entered a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC providing a secured term loan facility of up to $2.0 million to be used for working capital and general corporate purposes. Borrowings accrue interest at 10.0% per annum payable at maturity and the company will owe an Exit Fee equal to 10% of original principal ($200,000) if the loan matures. The loan matures upon the earlier of a Qualified Financing raising $2.4 million net proceeds or September 14, 2026. The lender may convert outstanding obligations into equity in connection with a Qualified Financing. The obligations are guaranteed by Ekso Bionics, Inc. and secured by substantially all personal property, and the agreement includes customary covenants, events of default and a potential default interest of +5.0% per annum above the base rate. The company simultaneously repaid and terminated its prior $2.0 million loan agreement with Banc of California.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 289,876 shares of Ekso Bionics Holdings, Inc., representing 9.99% of the outstanding common stock. Both reporting persons state they possess shared voting and dispositive power over these shares and no sole voting or dispositive power. Armistice Capital is the investment manager of the Armistice Capital Master Fund Ltd., which directly holds the reported shares, and the Master Fund retains the right to receive dividends or sale proceeds. The Master Fund disclaims beneficial ownership under its investment management agreement to the extent it cannot vote or dispose of the securities.